BRCA2 and breast cancer: In the future, this may also allow the introduction of risk-stratified screening which already exists to some extent in many screening programmes; the NHSBSP has already introduced very high-risk screening with MRI mainly in women with mutations in BRCA1, BRCA2, or TP53. The PROCAS study has shown that it is feasible to collect risk information and, using a good discriminating risk model, provide accurate assessments of women’s risk of BC, although further improvements in risk discrimination are needed.